Man & Science Completes Implantation in ONFIELD First-in-Human Study of Miniaturised ONS System for Chronic Cluster Headache
19.11.2026 08:00:00 CET | Business Wire | Press Release
Man & Science, a Belgian-based medical device company specialised in miniaturised neurostimulation technologies, today announced that all ten patients have been implanted and activated in its ONFIELD first-in-human pilot study of a miniaturised occipital nerve stimulation (ONS) implant for cluster headache, and that early clinical responses are encouraging.
The ONFIELD study is evaluating the safety and feasibility of the Man & Science implant in patients whose cluster headaches remain inadequately controlled despite available treatments. All ten patients planned for this stage of the study have now received the implant and are being followed by the participating clinical team. Early observations show reductions in attack frequency in the patients assessed to date. No serious adverse events related to the implant surgery or the device have been reported so far.
A severe and difficult-to-treat neurological disorder
Cluster headache is a severe neurological disorder characterised by recurrent attacks of intense pain, typically affecting one side of the head around the eye or temple. Attacks generally last between 15 minutes and three hours and can occur several times a day. For people living with chronic, refractory cluster headache, established treatments including high-flow oxygen, triptans and preventive medication may provide insufficient relief.
“Reaching ten implanted patients is an important milestone for the ONS programme and the early responses we are observing in these patients are encouraging”, says Professor Jean-Pierre Van Buyten, Chief Medical Officer and co-founder of Man & Science. “These are patients living with an extremely severe condition who have continued to experience frequent attacks despite available treatments. Our implant has been specifically designed and optimised for these patients, with the goal of improving both safety and patient outcomes.”
A miniaturised approach to occipital nerve stimulation
Man & Science has developed a miniaturised neurostimulation implant designed to stimulate the occipital nerve region as a single subcutaneous implant, with no tunnelled leads and no separately implanted battery. Today, occipital nerve stimulation is typically performed off-label with spinal cord stimulation hardware, which requires leads tunnelled under the skin to a pulse generator implanted elsewhere in the body.
“Our next priorities are to complete the ONFIELD study, continue evaluating safety and early efficacy signals, prepare for the pivotal clinical phase and advance the programme towards commercialisation”, says Hugues Wallemacq, CEO of Man & Science.
Subject to the final results of the pilot study and the applicable regulatory pathway, Man & Science plans to use the ONFIELD findings to support the next stage of clinical development, including a pivotal study designed to generate the evidence required for regulatory approval and future commercialisation. The company also sees potential for the technology in other indications involving peripheral nerve stimulation, including cervicogenic headache and occipital neuralgia, but its immediate focus is on progressing the cluster headache programme through pivotal development and towards market readiness.
About Man & Science
Man & Science SA is a privately held clinical-stage medical device company based in Liège, Belgium. The company develops next-generation, minimally invasive neuromodulation technologies for the treatment of severe neurological disorders. Its lead programmes include a minimally invasive occipital nerve stimulation (ONS) implant for chronic cluster headache and an injectable peripheral nerve stimulation (iPNS) platform designed to transform neuromodulation from a surgical to an injection-based procedure and broaden access to treatment for patients with severe migraine. Man & Science is backed by private investors, Noshaq, and Wallonie Entreprendre. For more information, visit www.manandscience.com.
Important note: The ONFIELD study is ongoing. The Man & Science ONS device is an investigational device: it is not CE-marked, not approved by the U.S. Food and Drug Administration and not available for sale.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261023368584/en/
Contacts
Press
Lownia Cora, lc@gosselindewalque.com, +32 471 69 36 51
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Summit Risk Partners Limited Opens for Business as a Registered Lloyd’s Broker Through its Regulated Subsidiaries19.11.2026 09:00:00 CET | Press Release
Summit Risk Partners Limited (SRP), a newly launched division of K2 Insurance Services, announced today it is officially open for business as a registered Lloyd’s broker. Built specifically for the future of delegated authority, SRP aims to elevate service provision and set a new standard for outcomes across delegated and programme business in the Lloyd’s and London markets. Co-founded by James Baird, CEO, and Jamie Beckett, Managing Director, the specialist broking house operates free from legacy systems and mindsets. SRP combines deep industry expertise with modern technology, actionable insight, and a relentless focus on client success for coverholders, MGAs, underwriting businesses and capacity providers. Key Operational Highlights: Market Status: Registered Lloyd’s broker trading under the pseudonym SUM (Broker Number 2336), sponsored by three leading Lloyd’s Managing Agents. Footprint: Operates in the UK through Summit RP GmbH (UK Branch), an appointed representative of K2 Group
Ant International Launches Whale Orchestration Protocol Under MAS’ BLOOM Initiative to Connect Tokenised Money Market Funds and Tokenised Deposits19.11.2026 07:00:00 CET | Press Release
Ant International today announced the launch of the Whale Orchestration Protocol, a major upgrade to its blockchain-based wholesale settlement platform, WhaleRTP. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118947513/en/ Developed under the Monetary Authority of Singapore’s (MAS) BLOOM1 (Borderless, Liquid, Open, Online, Multi-currency) initiative, the protocol enables seamless Delivery-versus-Payment (DvP) transactions between tokenised deposits and tokenised money market funds. Through WhaleRTP, the Whale Orchestration Protocol enables secure and atomic settlement between tokenised deposits and tokenised money market funds, overcoming traditional fund settlement delays. This unlocks immediate liquidity for the company's real-time global treasury management, allowing idle capital to be deployed in real time. Ant International has already completed pilot transactions in partnership with DBS and Franklin Templeton, who
RSA Compliance Advisor Closes the Governance Gaps Between Audits19.11.2026 07:00:00 CET | Press Release
RSA, the identity standard for government agencies, finance, and high-assurance organizations, today announced the general availability of RSA Compliance Advisor, a new capability within RSA® Governance & Lifecycle, the RSA identity governance and administration (IGA) solution, that maps identity governance controls directly to regulatory requirements and reports on compliance posture continuously. Governments and regulators keep raising the bar. GDPR, CJIS, HIPAA, NIST, and POPIA each carry hundreds of requirements, and new regulatory activity keeps adding more. Despite growing regulatory requirements, most compliance programs still confirm their posture the way they did a decade ago: quarterly reviews, annual certifications, manually built spreadsheets. This reactive, periodic assessment doesn’t account for access that changes every day in between. A program built on point-in-time checkpoints can look compliant on the day of the audit and still carry risk that never gets seen. RSA Co
NETS and Ant International Deepen Partnership to Empower Singapore’s Businesses for a Future in Agentic Commerce with Agentic Mobile Protocol19.11.2026 06:30:00 CET | Press Release
Network for Electronic Transfers (NETS), Singapore’s leading payment services group, and Ant International are deepening their partnership to help businesses across Singapore reach new customers, simplify their operations and thrive in the era of agentic commerce by building a more connected mobile ecosystem well adapted to the AI era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118997808/en/ Lawrence Chan, Group CEO, NETS (L) and Peng Yang, CEO, Ant International (R) NETS and Ant International signed a Memorandum of Understanding (MOU) at the Singapore Fintech Festival 2026 to explore a collaboration that draws on NETS’ digital payments services and Ant International’s Agentic Mobile Protocol (AMP) as well as its full stack of AI-native solutions. The expanded partnership spans several areas of strategic cooperation: Bringing agentic commerce capabilities to businesses of all sizes across Singapore NETS will become th
SBC Medical Group Reports Cybersecurity Incidents in Japan19.11.2026 05:39:00 CET | Press Release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ("SBC Medical Group" or the "Company"), a provider of comprehensive management services to medical corporations and their clinics, today reported the occurrence of recent cybersecurity incidents involving customer information associated with certain clinics in Japan, along with the status of its response. Overview of the Incidents On November 16, 2026, unauthorized access occurred to certain databases within a website system managed and operated by SBC Medical Group, Ltd., the Company’s, Japanese subsidiary, in connection with its management services in Japan. The Company confirmed that an unauthorized third party accessed and extracted customer information. The method of intrusion and full scope remain under investigation. Based on current information, the information obtained and the number of affected customers are as follows: Category Types of information Individuals Period Basic personal information (without reservation or trea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom